Pharmaceutical composition containing acylated insulin

By optimizing the components and pH value of acylated insulin formulations, the stability problem of insulin formulations has been solved, resulting in a longer shelf life and better efficacy, making them suitable for medical products.

WO2026109062A1PCT designated stage Publication Date: 2026-05-28GAN & LEE PHARM CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2025/137614
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-10-27
Filing Date
2025-11-25
Publication Date
2026-05-28

AI Technical Summary

Technical Problem

Existing insulin formulations suffer from chemical and physical stability issues during storage and are not administered frequently enough to meet the demands for longer duration of action and better efficacy.

Method used

The formulation employs a pharmaceutical preparation containing acylated insulin, zinc ions, preservatives, tension modifiers, and a buffer solution. The buffer solution contains citric acid or citrate and has a pH of 6.5-8.5. The stability of the formulation is improved by optimizing the component ratio and pH value.

Benefits of technology

It achieves excellent chemical and physical stability of pharmaceutical preparations, extends shelf life, and improves efficacy, making it suitable for use as a medical product.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2025137614_28052026_PF_FP_ABST
    Figure CN2025137614_28052026_PF_FP_ABST
Patent Text Reader

Abstract

Provided are an acylated insulin preparation, a pharmaceutical composition of acylated insulin and a long-acting GLP-1 compound, and the medical use thereof. The preparation and the pharmaceutical composition have satisfactory physical stability, chemical stability, and safety.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Pharmaceutical composition containing insulin

    CN115154591A

  • Novel insulin derivative and use thereof

    CN116789801A

  • Pharmaceutical composition containing acylated insulin

    CN118139875A

  • A novel acylated insulin analog

    US20240374692A1

  • Long-acting GLP-1 compound

    WO2021136303A1